Bentysrepinine

Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields[1][2].

Product Specifications

CAS Number

[934264-38-7]

Product Name Alternative

Y101

UNSPSC

12352005

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bentysrepinine.html

Smiles

CN(C)CCOC(C=C1)=CC=C1C[C@H](NC(C2=CC=CC=C2)=O)C(N[C@H](CO)CC3=CC=CC=C3)=O

Molecular Formula

C29H35N3O4

Molecular Weight

489.61

References & Citations

[1]Fan H, et al. Metabolite identification of bentysrepinine (Y101), a novel anti-HBV agent in rats using a five-step strategy based on a combined workflow with two different platforms of liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:118-128.|[2]Fan H, et al. In vitro metabolism and in vivo pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison. Xenobiotica. 2020 Apr;50 (4) :468-478.